Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France

Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France: Surgical Thresholds, Geographical Distance, Age and Therapeutic Sequence

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05204342

Acronym

Pro-TOCa

Enrollment

22500

Registered

2022-01-24

Start date

2012-01-01

Completion date

2021-12-30

Last updated

2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Keywords

Ovarian or Tubal Cancer, Upfront surgery, surgical thresholds

Brief summary

Evaluation of the following prognostic factors in France, based on national quotation data: volume per center, patient age, geographic distance from a clinical center, delay for chemotherapy,Upfront surgery.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \- Diagnosic of Ovarian or Tubal Cancer C56 et C570 * +/- * Carcinose péritonéale C786 * Tumueur maligne secondaire de la plèvre C782, * Tumueur maligne secondaire des ganglions C770 à C779, * Tumueur maligne secondaire du foie C787, * Tumueur maligne secondaire du péritoine C786

Exclusion criteria

* autres causes de : * Carcinose péritonéale C786 * Tumueur maligne secondaire de la plèvre C782, * Tumueur maligne secondaire des ganglions C770 à C779, * Tumueur maligne secondaire du foie C787, * Tumueur maligne secondaire du péritoine C786

Design outcomes

Primary

Measure	Time frame	Description
To study the prognostic effect of the volume of activity	at 5 years	To study the prognostic effect of the volume of activity per center on the risk of recurrence
Verify that the therapeutic sequence	at 5 years	Verify that the therapeutic sequence of primary surgery and secondary chemotherapy is a good prognostic factor for overall and specific survival at 5 years

Secondary

Measure	Time frame	Description
Verify that delay in initiation of chemotherapy beyond 4 weeks	at 5 years	Verify that delay in initiation of chemotherapy beyond 4 weeks after surgery is a poor prognostic element on overall and specific survival at 5 years
Verify that age is a poor prognostic element	at 5 years	Verify that age is a poor prognostic element for overall and specific survival at 5 years
Verify that geographic distance	at 5 years	Verify that geographic distance from a clinical center is a poor prognostic element for overall and specific survival at 5 years

Countries

France

Outcome results